BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF)(TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation (OMRF) and current InNexus Scientific Advisory Board (SAB) Chairman, joined its Board of Directors.
